BioMedNewsBreaks

FridayJun 19, 2020 1:46 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Develops Potential, Nonsurgical Solution for Obstructive Sleep Apnea

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article further discussing the company reads, “This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development — the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18-to-24-month…

Continue Reading

ThursdayJun 18, 2020 12:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (“PDx”) through its distributor US Biological Corporation. According to the update, the media used to grow the novel and unique ovarian cancer cell lines, licensed by TumorGenesis and its partner, GLG Pharma, are able to retain 95%+ of the DNA and RNA as well as crucial proteomic signatures. “Capturing and culturing and then being able…

Continue Reading

TuesdayJun 16, 2020 12:45 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. According to the update, the new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. “We are pleased with continued progress in the scale-up of our manufacturing processes,” Rodney Varner, chairman and CEO of Genprex, said in…

Continue Reading

WednesdayJun 10, 2020 12:53 pm

BioMedNewsBreaks – Why Vivos Therapeutics Inc. Is ‘One to Watch’

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), is on a mission to eliminate OSA using its revolutionary Vivos System(R), a clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. An article discussing the company reads, “Designed to promote correct growth and development of the hard and soft tissues surrounding and compromising the oral cavity, nasal cavity, upper and lower jaws, and other tissues that comprise and shape the human airway. The system uses Pneumopedics(R), the natural process induced by Vivos biomimetic technology to widen and expand the patient’s airway,…

Continue Reading

TuesdayJun 09, 2020 10:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Selected to Join Russell 3000(R) Index

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the 3,000 publicly traded companies on the Nasdaq and NYSE exchanges with the largest market capitalizations. According to the update and a preliminary list of additions, Genprex will join the index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26, 2020. “The selection of Genprex for the Russell 3000(R) Index will add to the awareness…

Continue Reading

TuesdayJun 09, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain steadfast in our approach to assembling a portfolio of assets that leverages our unique collection of cancer tumors to develop and market AI-based, predictive models for personalized cancer treatments that improve patient outcomes,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “Our collection of more than 150,000 cancer tumors, amassed and curated over a 10-year period, gives us a…

Continue Reading

MondayJun 08, 2020 10:11 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Chairman and CEO to Present at the MoneyShow June Virtual Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the update, Genprex’s CEO and Chairman, Rodney Varner, will deliver a company overview and provide updates on its product pipeline, including its lead drug candidate, Oncoprex(TM) immunogene therapy, which received Fast Track Designation from the Food and Drug Administration for its combination therapy with AstraZeneca’s Tagrisso(R). He will also provide an overview of Genprex’s in-licensing of a preclinical gene…

Continue Reading

WednesdayJun 03, 2020 9:32 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, Inc. Included in the acquisition were certain intellectual property relating to contract research organization (“CRO”) services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech. In consideration, POAI issued 125,000 shares of common stock and waived all remaining amounts due and payable to the company under a secured promissory note…

Continue Reading

MondayJun 01, 2020 2:09 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist…

Continue Reading

FridayMay 29, 2020 1:10 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory

Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive BMW interview with Stuart Smith (http://nnw.fm/54qVZ). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring physicians…

Continue Reading